TradeFlare's AI research teams analysed MGTX on 11 market nights between April 28, 2026 and September 10, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| September 10, 2026 | BUY | $13.26 | $19.22 / $11.27 | +1.6% | -18.3% | The fundamental and sentiment catalysts suggest a medium-term upward trend. |
| July 27, 2026 | BUY | $11.77 | $14.12 / $9.90 | -3.4% | +20.6% | The bullish fundamental and sentiment outlook, coupled with a technical oversold bounce signal, suggests a medium-term recovery potential. |
| May 26, 2026 | HOLD | $9.24 | — / — | -3.8% | +20.8% | Positive clinical trial data for gene therapy candidates. |
| May 25, 2026 | HOLD | $9.24 | — / — | -3.8% | +20.8% | Positive clinical trial data for lead asset. |
| May 21, 2026 | BUY | $9.58 | — / — | +12.2% | +21.0% | Positive clinical trial data for pipeline assets. |
| May 20, 2026 | BUY | $9.13 | — / — | +4.4% | +18.2% | Positive clinical trial data for pipeline drugs. |
| May 19, 2026 | HOLD | $9.40 | — / — | +8.3% | +14.0% | Positive clinical trial data for gene therapy candidates. |
| May 18, 2026 | HOLD | $9.40 | — / — | +2.1% | +3.3% | Positive clinical trial data for gene therapy candidates. |
| April 30, 2026 | HOLD | $8.95 | — / — | +5.0% | +15.5% | Positive clinical trial data readouts for pipeline assets. |
| April 29, 2026 | BUY | $9.08 | — / — | +10.6% | +11.7% | The current market conditions and the stock's technicals do not present a clear, high-conviction trading opportunity. |
| April 28, 2026 | BUY | $9.13 | $10.28 / $7.76 | +7.4% | +8.9% | The neutral market regime and the high risk score necessitate a cautious approach, waiting for clearer signals. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.